Reference specification at a glance
TB-500 naming alone is insufficient to specify the material. Confirm the exact sequence, molecular identity and source documents rather than assuming it is interchangeable with full-length thymosin beta-4. No injury-recovery claim is made.
- Ingredient
- TB-500
- Target amount per strip
- 500 mcg
- Format
- Oral dissolving film concept
- Packaging
- Individual barrier sachets; carton count confirmed per project
- Availability
- Subject to feasibility and regulatory acceptance
The amount above is a supplier-provided reference specification, not a dosing instruction or evidence of clinical efficacy. No approval, absorption or equivalence to another dosage form is implied.
Request a qualified project reviewWhat must be confirmed before a prototype?
A product name and target loading are not sufficient to establish a production-ready oral film. Review starts with the precise material identity, supplier documentation, intended use and destination country. Film loading and handling, analytical methods, content uniformity and packaged stability must be demonstrated for the actual formulation. Final specifications are agreed from evidence rather than assumed from the reference amount. Commercial progression requires the appropriate authorized pathway; a research label does not make human-use marketing lawful.
- Exact material identity and specification, with a representative COA
- Target market, intended classification and authorized applicant where required
- Finished-film assay, uniformity and stability acceptance criteria
- Film dimensions, flavour, sachet barrier and seal requirements
How is this concept different from a finished medicine?
This page describes a development brief rather than an approved product, clinical recommendation or consumer treatment. Oral disintegration does not demonstrate sublingual absorption or bioavailability. Evidence and approvals for another formulation cannot be transferred automatically to an oral film. Development images illustrate packaging only; they do not establish ingredient identity, potency, safety or manufacturing validation. Before any commercial commitment, the parties must confirm legal eligibility, manufacturing authorization, study requirements and the approved label for the intended jurisdiction.
Regulatory context: FDA guidance on unapproved GLP-1 products.
Questions for an OEM enquiry
Is 500 mcg a recommended daily dose?
No. It is reference content per film supplied for project scoping. This catalogue provides no patient instructions, frequency, treatment cycle or dose conversion.
Can the packaging and target loading be customized?
They can be reviewed as part of the brief. Acceptance depends on the formulation, evidence package, manufacturing controls and lawful market pathway; customization is not a guarantee of feasibility.
What should a qualified buyer send?
Provide the ingredient specification and COA, proposed market and classification, target loading, packaging brief and authorized development context. Review our development services or contact the project team.